Shenouda Maged

CFO Shenouda Maged buys 11,665 shares of RLMD at $4.12; stock now at $4.50 (+13.9% in 30d), but company reports -35.4% revenue decline YoY.

Shenouda Maged, the Chief Financial Officer, purchased 11,665 shares at $4.12 on 2025-12-15, bringing his holdings to 800,000 shares (an increase of 1.5%). The purchase occurs in a context of strong recent momentum: the stock has gained 13.9% in the last 30 days and 198.0% over the past 90 days, and is currently trading at $4.50. However, this near-highs purchase (stock at -0.2% from 52-week high) occurs while the company faces significant operational headwinds: annual revenue has declined 35.4% year-over-year, the company posted a net loss of $-10.1M in the latest quarter, and full-year results show the company is unprofitable. Maged's same-ticker history shows 3 of 4 prior buys at RLMD produced positive 90-day returns, including his most recent purchase on 2025-11-05 which returned +92.7% at the 30-day mark; however, his earlier buy on 2024-09-11 subsequently declined 84.1% over 90 days, indicating timing accuracy is inconsistent at this ticker. The divergence between strong price action, insider buying by the CFO, and deteriorating fundamentals merits attention to whether near-term momentum masks underlying business stress.

CFO Shenouda Maged buys 500,000 shares of RLMD at $2.20; holdings rise 173.4%; company unprofitable with -35.4% annual revenue decline.

Shenouda Maged, CFO of Relmada Therapeutics, purchased 500,000 shares at $2.20 on 2025-11-05, increasing his holdings from 288,335 shares to 788,335 shares (+173.4%). This is a material open-market acquisition of $1,100,000.00. The timing follows strong near-term momentum: the stock is up +31.2% over 30 days and +344.3% over 90 days from the transaction date. However, this buy occurs against a backdrop of deteriorating fundamentals: the company posted net income of $-9,866,442.00 (negative) in its most recent full fiscal year, with annual revenue declining -35.4% year-over-year and latest quarterly revenue of only $682.00. At Relmada specifically, Maged's prior five trades show a 60% timing success rate (3 of 5 well-timed at the 90-day mark), with recent May 2025 buys posting +26.8% to +37.4% 90-day returns; earlier 2024 buys posted steep 90-day declines of -82.4% and -84.1%. The current purchase is concurrent with a cluster of three other insider buys within 14 days, suggesting coordinated appetite despite the company's negative earnings trajectory.

CFO Shenouda Maged buys 200,000 shares at avg $0.49; prior RLMD buys all underwater at 90 days (0 of 5 well-timed)

Shenouda Maged, CFO, executed 3 separate purchases totaling 200,000 shares for $97,208.00 at a blended average price of $0.49 across May 16–20, increasing his holdings from 88,335 shares to 288,335 shares (+226.4%). This cluster activity coincides with 3 other insiders buying within the past 14 days. However, Maged's prior trade pattern at RLMD is concerning: his last 5 open-market buys at this ticker posted a 0 of 5 success rate at the 90-day mark, with losses ranging from -84.1% to -10.4%. The company is unprofitable (net income $-17,559,465.00), generated only $682.00 in latest quarterly revenue, and contracted -35.4% year-over-year. Current price is $0.60, down -86.2% from the 52-week high of $4.36. This purchase at $0.49 reflects accumulation at depressed levels, but the consistent failure of Maged's prior RLMD purchases to recover within 90 days is a material red flag for near-term upside risk.

CFO Shenouda Maged buys 53,432 shares for $149.7K across 3 trades; holdings +153.1%; cluster buy pattern observed

Shenouda Maged, CFO of Relmada Therapeutics, executed 3 separate purchases totaling 53,432 shares for $149,700.84 at a blended average price of $2.80 between September 9–11, 2024. This acquisition increased his holdings from 34,903 to 88,335 shares (+153.1%). The company's fundamentals are challenged: most recent quarterly revenue was $682.00, the company posted a net loss of $-17,768,122.00 on an annualized basis, and annual revenue declined -35.4% year-over-year; market cap stands at $91,126,090.04. The current stock price of $3.02 sits -55.6% below its 52-week high of $6.80, though it has risen +31.3% over the past 30 days. Notably, 3 other insiders also bought within the past 14 days, forming a cluster buy pattern. His prior trades at this ticker have shown mixed timing results: of 3 prior buys at RLMD, only 1 achieved a positive 90-day return, suggesting inconsistent predictive value from historical execution at this specific security.